FDA — authorised 21 December 2017
- Application: NDA209360
- Marketing authorisation holder: LA JOLLA PHARMA
- Indication: Type 1 - New Molecular Entity
- Status: approved
🇺🇸 Angiotensin Ii in United States
FDA authorised Angiotensin Ii on 21 December 2017
Marketing authorisations
FDA — authorised 3 June 2025
- Application: ANDA216966
- Marketing authorisation holder: GLAND
- Status: approved
FDA
- Marketing authorisation holder: GLAND
- Status: approved
Angiotensin Ii in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Hematology approved in United States
Frequently asked questions
Is Angiotensin Ii approved in United States?
Yes. FDA authorised it on 21 December 2017; FDA authorised it on 3 June 2025; FDA has authorised it.
Who is the marketing authorisation holder for Angiotensin Ii in United States?
LA JOLLA PHARMA holds the US marketing authorisation.